MarketCap
Facebook
X
TelegramAnnual report 2023
added 02-29-2024
PetIQ Operating Income 2011-2026 | PETQ
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income PetIQ
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 37.1 M | -20.2 M | 15.9 M | -3.19 M | -3.14 M | 7.75 M | 13.3 M | 702 K | 3.57 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 37.1 M | -20.2 M | 5.75 M |
Quarterly Operating Income PetIQ
| 2023-Q3 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.36 M | - | -42.5 M | 11.4 M | 9.4 M | - | -3.18 M | 16.5 M | 7.13 M | - | -3.29 M | 3.69 M | 464 K | -12.6 M | -4.36 M | 8.99 M | 4.87 M | -4.85 M | 6.91 M | 8.92 M | -3.23 M | 42 K | 1.78 M | 6.67 M | 4.8 M | 116 K | -1.78 M | 659 K | 1.71 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 16.5 M | -42.5 M | 1.06 M |
Operating Income of other stocks in the Drug manufacturers industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Cumberland Pharmaceuticals
CPIX
|
-1.84 M | $ 4.18 | -4.23 % | $ 58.8 M |  USA |
 |
AcelRx Pharmaceuticals
ACRX
|
-13.5 M | - | 7.5 % | $ 6.35 M | USA |
 |
DURECT Corporation
DRRX
|
-36.9 M | - | - | $ 50.1 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-25.1 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-46.4 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
-19.9 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
-1.93 M | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
-70 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-42.4 M | - | - | $ 2.06 B |  France |
 |
Catalent
CTLT
|
-749 M | - | - | $ 11.5 B | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-524 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-85.5 M | - | 2.45 % | $ 38.1 M |  Canada |
 |
Eagle Pharmaceuticals
EGRX
|
81 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
-469 M | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
-7.43 M | - | - | $ 36.6 M | USA |
 |
Bausch Health Companies
BHC
|
963 M | $ 5.67 | 0.27 % | $ 2.07 B | Canada |
 |
Organogenesis Holdings
ORGO
|
-1.28 M | $ 2.64 | 2.93 % | $ 348 M | USA |
 |
Pacira BioSciences
PCRX
|
-73.4 M | $ 23.8 | 0.46 % | $ 1.1 B | USA |
 |
Canopy Growth Corporation
CGC
|
-117 M | $ 1.14 | -0.87 % | $ 123 M | Canada |
 |
Harrow Health
HROW
|
30.5 M | $ 39.52 | -1.87 % | $ 1.45 B | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-3.71 M | $ 1.17 | -1.68 % | $ 1.45 M | USA |
 |
Solid Biosciences
SLDB
|
-179 M | $ 6.98 | -3.06 % | $ 611 M | USA |
 |
Aurora Cannabis
ACB
|
-283 M | $ 3.5 | -1.27 % | $ 86.3 M | Canada |
 |
Lannett Company
LCI
|
-176 M | - | 1.15 % | $ 7.11 M | USA |
 |
Tilray
TLRY
|
-1.37 B | $ 5.79 | 0.43 % | $ 3.58 B | Canada |
 |
OrganiGram Holdings
OGI
|
-35.7 M | $ 1.4 | 0.36 % | $ 133 M | Canada |
 |
Evolus
EOLS
|
-32.7 M | $ 6.57 | 3.96 % | $ 424 M | USA |
 |
Sundial Growers
SNDL
|
-132 M | $ 1.46 | 1.04 % | $ 3.37 M | Canada |
 |
Veru
VERU
|
-36.9 M | $ 2.27 | 2.1 % | $ 306 M | USA |
 |
Emergent BioSolutions
EBS
|
-726 M | $ 9.15 | 0.16 % | $ 468 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-103 M | - | - | $ 193 M | Canada |
 |
cbdMD
YCBD
|
-3.32 M | $ 0.88 | -4.32 % | $ 3.8 M | USA |
 |
ProPhase Labs
PRPH
|
23.6 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
-54.3 M | - | - | $ 1.42 B | USA |
 |
Assertio Holdings
ASRT
|
-21.5 M | $ 22.32 | 0.54 % | $ 143 M | USA |
 |
Relmada Therapeutics
RLMD
|
-59.1 M | $ 7.62 | -3.05 % | $ 301 M | USA |
 |
Recro Pharma
REPH
|
-3.57 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
-22.7 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
-16.1 M | $ 0.97 | -1.71 % | $ 48.4 M | USA |
 |
PLx Pharma
PLXP
|
-40.8 M | - | -27.8 % | $ 2.56 M | USA |
 |
Viatris
VTRS
|
766 M | $ 16.91 | 6.02 % | $ 20.3 B | USA |
 |
Zomedica Corp.
ZOM
|
-84.4 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-35.3 M | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
-4.69 M | $ 0.78 | -3.7 % | $ 28.1 M | USA |
 |
Tricida
TCDA
|
-153 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
-3.24 M | $ 0.52 | -1.96 % | $ 2.23 M |  China |
 |
TherapeuticsMD
TXMD
|
-4.39 M | $ 2.04 | 0.44 % | $ 23.6 M | USA |